Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Price:
964.8
INR
-0.72%
Market Closed
Market Cap:
970.8B
INR
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
ZYDUSLIFE Alert
Zydus Lifesciences Ltd
964.8
-7.0 (-0.72%)
| 52 Week Range |
676.2
1 302
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Zydus Lifesciences Ltd
Balance Sheet
Balance Sheet Decomposition
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
| Current Assets | 115B |
| Cash & Short-Term Investments | 20.5B |
| Receivables | 60.5B |
| Other Current Assets | 34.1B |
| Non-Current Assets | 177.8B |
| Long-Term Investments | 9.7B |
| PP&E | 69.1B |
| Intangibles | 78.8B |
| Other Non-Current Assets | 20.2B |
| Current Liabilities | 53.4B |
| Accounts Payable | 21.3B |
| Accrued Liabilities | 12.7B |
| Short-Term Debt | 7.7B |
| Other Current Liabilities | 11.8B |
| Non-Current Liabilities | 41.1B |
| Long-Term Debt | 251m |
| Other Non-Current Liabilities | 40.8B |
Balance Sheet
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
Currency: INR
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
6 178
|
6 387
|
15 435
|
13 149
|
6 493
|
9 649
|
8 883
|
11 069
|
5 731
|
11 051
|
|
| Cash |
6 178
|
6 387
|
15 435
|
13 149
|
6 493
|
9 649
|
8 883
|
11 069
|
5 731
|
4 130
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6 921
|
|
| Short-Term Investments |
1 323
|
2 129
|
614
|
2 748
|
2 299
|
2 815
|
3 933
|
29 749
|
6 998
|
9 400
|
|
| Total Receivables |
18 394
|
19 969
|
24 942
|
37 189
|
46 514
|
43 564
|
38 518
|
39 395
|
50 816
|
60 473
|
|
| Accounts Receivables |
16 303
|
17 466
|
22 775
|
32 063
|
39 508
|
36 632
|
31 273
|
33 403
|
44 278
|
52 312
|
|
| Other Receivables |
2 091
|
2 503
|
2 167
|
5 126
|
7 006
|
6 932
|
7 245
|
5 992
|
6 538
|
8 161
|
|
| Inventory |
14 713
|
14 038
|
18 765
|
24 897
|
27 658
|
28 746
|
33 783
|
38 982
|
35 791
|
35 977
|
|
| Other Current Assets |
279
|
281
|
467
|
4 314
|
2 017
|
2 380
|
2 043
|
3 419
|
1 681
|
5 034
|
|
| Total Current Assets |
40 887
|
42 804
|
60 223
|
82 297
|
84 981
|
87 154
|
87 160
|
122 614
|
100 164
|
115 014
|
|
| PP&E Net |
31 183
|
35 575
|
48 337
|
53 429
|
59 431
|
61 937
|
63 332
|
64 226
|
68 267
|
69 148
|
|
| PP&E Gross |
31 183
|
35 575
|
48 337
|
53 429
|
59 431
|
61 937
|
63 332
|
64 226
|
68 267
|
69 148
|
|
| Accumulated Depreciation |
12 081
|
14 771
|
17 609
|
21 001
|
26 237
|
31 258
|
36 253
|
39 059
|
45 026
|
50 818
|
|
| Intangible Assets |
393
|
2 466
|
13 153
|
12 816
|
17 688
|
13 868
|
12 363
|
11 272
|
10 905
|
26 110
|
|
| Goodwill |
8 950
|
8 946
|
11 494
|
13 853
|
52 890
|
53 915
|
53 465
|
53 646
|
48 044
|
52 660
|
|
| Note Receivable |
3 020
|
3 778
|
4 075
|
1 368
|
2 005
|
979
|
1 477
|
1 792
|
2 001
|
1 759
|
|
| Long-Term Investments |
1 970
|
2 171
|
3 857
|
4 709
|
4 436
|
5 522
|
6 312
|
9 348
|
11 779
|
9 696
|
|
| Other Long-Term Assets |
4 939
|
9 766
|
11 068
|
12 181
|
13 400
|
13 491
|
14 738
|
15 056
|
16 404
|
18 421
|
|
| Other Assets |
8 950
|
8 946
|
11 494
|
13 853
|
52 890
|
53 915
|
53 465
|
53 646
|
48 044
|
52 660
|
|
| Total Assets |
91 342
N/A
|
105 506
+16%
|
152 207
+44%
|
180 653
+19%
|
234 831
+30%
|
236 866
+1%
|
238 847
+1%
|
277 954
+16%
|
257 564
-7%
|
292 808
+14%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
10 329
|
13 081
|
16 736
|
18 884
|
19 226
|
20 310
|
22 059
|
21 378
|
21 250
|
21 267
|
|
| Accrued Liabilities |
3 232
|
3 960
|
6 344
|
9 290
|
9 938
|
8 658
|
9 382
|
11 414
|
13 077
|
12 702
|
|
| Short-Term Debt |
11 757
|
12 109
|
24 769
|
25 575
|
31 969
|
38 265
|
30 709
|
33 141
|
10 810
|
7 686
|
|
| Current Portion of Long-Term Debt |
3 174
|
3 347
|
2 619
|
2 941
|
7 528
|
9 582
|
9 121
|
5 286
|
941
|
105
|
|
| Other Current Liabilities |
1 429
|
2 113
|
2 590
|
4 140
|
4 764
|
5 879
|
7 342
|
7 175
|
9 229
|
11 659
|
|
| Total Current Liabilities |
29 921
|
34 610
|
53 058
|
60 830
|
73 425
|
82 694
|
78 613
|
78 394
|
55 307
|
53 419
|
|
| Long-Term Debt |
11 504
|
8 964
|
24 684
|
25 551
|
39 497
|
32 291
|
6 246
|
3 782
|
198
|
251
|
|
| Deferred Income Tax |
1 575
|
2 009
|
1 164
|
2 821
|
2 523
|
2 099
|
1 197
|
1 538
|
1 944
|
4 465
|
|
| Minority Interest |
1 767
|
1 358
|
1 561
|
1 910
|
12 929
|
13 347
|
19 373
|
20 542
|
21 725
|
22 721
|
|
| Other Liabilities |
1 367
|
1 573
|
2 140
|
2 096
|
2 594
|
2 678
|
3 495
|
3 702
|
3 232
|
13 657
|
|
| Total Liabilities |
46 134
N/A
|
48 514
+5%
|
82 607
+70%
|
93 208
+13%
|
130 968
+41%
|
133 109
+2%
|
108 924
-18%
|
107 958
-1%
|
82 406
-24%
|
94 513
+15%
|
|
| Equity | |||||||||||
| Common Stock |
1 024
|
1 024
|
1 024
|
1 024
|
1 024
|
1 024
|
1 024
|
1 024
|
1 012
|
1 006
|
|
| Retained Earnings |
44 184
|
56 413
|
68 683
|
85 919
|
103 919
|
106 711
|
132 017
|
173 133
|
181 441
|
206 341
|
|
| Other Equity |
0
|
445
|
107
|
502
|
1 080
|
3 978
|
3 118
|
4 161
|
7 295
|
9 052
|
|
| Total Equity |
45 208
N/A
|
56 992
+26%
|
69 600
+22%
|
87 445
+26%
|
103 863
+19%
|
103 757
0%
|
129 923
+25%
|
169 996
+31%
|
175 158
+3%
|
198 295
+13%
|
|
| Total Liabilities & Equity |
91 342
N/A
|
105 506
+16%
|
152 207
+44%
|
180 653
+19%
|
234 831
+30%
|
236 866
+1%
|
238 847
+1%
|
277 954
+16%
|
257 564
-7%
|
292 808
+14%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1 024
|
1 024
|
1 024
|
1 024
|
1 024
|
1 024
|
1 024
|
1 024
|
1 012
|
1 006
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
